MS

Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Wed, 03/27/19 - 10:20 am
Celgene
ozanimod
MS
multiple sclerosis
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
GeNeuro finds path forward for temelimab in non-active progressive MS
BioCentury
Tue, 03/12/19 - 07:37 pm
GeNeuro
MS
temelimab
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Mon, 03/11/19 - 10:25 pm
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
New insight into how Biogen's Tecfidera works may lead to better MS therapies
Fierce Biotech
Sat, 03/2/19 - 12:49 pm
Biogen
Tecfidera
MS
multiple sclerois
R&D
FDA Accepts for Review Alkermes' and Biogen's NDA for Multiple Sclerosis Drug
CP WIre
Mon, 02/25/19 - 12:24 pm
Alkermes
Biogen
diroximel fumarate
MS
multiple sclerosis
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pharmaforum
Mon, 01/7/19 - 11:20 am
Biogen
CNS
Alzheimer's disease
MS
C4 Therapeutics
Skyhawk Therapeutics
Blocking brain inflammation in multiple sclerosis with gut immune cells
Fierce Biotech
Fri, 01/4/19 - 09:08 am
inflammation
MS
multiple sclerosis
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Tue, 12/18/18 - 10:28 am
Alkermes
Biogen
MS
multiple sclerosis
Vumerity
FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears
Fierce Pharma
Fri, 11/30/18 - 12:20 pm
Sanofi
Lemtrada
FDA
stroke
MS
Novartis confident in Gilenya despite FDA call out
Biopharma Dive
Wed, 11/21/18 - 01:09 pm
Novartis
Gilenya
MS
multiple sclerosis
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Reuters
Wed, 10/24/18 - 11:46 pm
Biogen
Tecfidera
MS
Forward Pharma
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Mon, 10/15/18 - 12:13 pm
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Endpoints
Fri, 10/12/18 - 12:20 pm
Merck KGaA
evobrutinib
MS
multiple sclerosis
Gilenya beats Copaxone head-to-head at higher dose, study finds
Biopharma Dive
Thu, 10/11/18 - 11:13 pm
Novartis
Teva Pharmaceutical
MS
Copaxone
Gilenya
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Fierce Pharma
Thu, 10/11/18 - 12:06 pm
Sanofi
Lemtrada
MS
multiple sclerosis
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Thu, 10/11/18 - 09:35 am
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Roche unveils long-term data from MS blockbuster Ocrevus
Pharmaforum
Wed, 10/10/18 - 10:24 am
Roche
Ocrevus
relapsing multiple sclerosis
MS
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Endpoints
Mon, 10/8/18 - 10:45 am
Novartis
siponimod
MS
multiple sclerosis
Europe

Pages